有外层视网膜管状结构的AMD患者抗VEGF治疗评价一例被引量：1

下载PDF

导出

摘要患者，男，72岁。因左眼视物不清1年并加重2个月于2013年12月12日来诊，患者诉右眼视物不清10余年，既往高血压病史10余年，药物治疗后血压正常；2年前曾患脑血管梗塞。

作者马雅贞袁源智

机构地区复旦大学附属中山医院眼科

出处《中华实验眼科杂志》 CAS CSCD 北大核心 2016年第2期114-115,共2页 Chinese Journal Of Experimental Ophthalmology

关键词抗VEGF治疗患者管状结构 AMD 视网膜视物不清高血压病史脑血管梗塞

分类号 R774.5 [医药卫生—眼科]

引文网络
相关文献

参考文献15

1LalwaniGA,RosenfeldPJ,FungAE,et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration:year 2 of the PrONTO Study[J].Am J Ophthalmol,2009,148(1)∶43–58. DOI:10.1016/j.ajo.2009.01.024.
2邹海东,张皙,许迅,柏林.低视力者生活质量量表中文版的研制和信度与效度考评[J].中华眼科杂志,2005,41(3):246-251. 被引量：164
3BresslerNM. Age-related macular degeneration is the leading cause of blindness[J].JAMA,2004,291(15)∶1900–1901.
4SmithW,AssinkJ,KleinR,et al. Risk factors for age-related macular degeneration:Pooled findings from three continents[J].Ophthalmology,2001,108(4)∶697–704.
5JagerRD,MielerWF,MillerJW. Age-related macular degeneration[J].N Engl J Med,2008,358(24)∶2606–2617. DOI:10.1056/NEJMra0801537.
6中国老年性黄斑变性临床诊断治疗路径[J].中华眼底病杂志,2013,29(4):343-355. 被引量：160
7American Academy of Ophthalmology Retina/Vitreous Panel. Preferred Practice Pattern?Guidelines. Age-Related Macular Degeneration[M].San Francisco,CA:American Academy of Ophthalmology;2015. Available at:www.aao.org/ppp.
8RosenfeldPJ,BrownDM,HeierJS,et al. Ranibizumab for neovascular age-related macular degeneration[J].N Engl J Med,355(14)∶1419–1431.
9AveryRL,PieramiciDJ,RabenaMD,et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration[J].Ophthalmology,2006,113(3)∶363–372.
10KodjikianL,DecullierE,SouiedEH,et al. Bevacizumab and ranibizumab for neovascular age-related macular degeneration:an updated meta-analysis of randomised clinical trials[J].Graefes Arch Clin Exp Ophthalmol,2014,252(10)∶1529–1537. DOI:10.1007/s00417–014–2764–6.

二级参考文献84

1邹海东,张晳,许迅,汪枫桦,张世杰.上海市静安区曹家渡街道年龄相关性黄斑变性的患病率调查[J].中华眼科杂志,2005,4(1):15-19. 被引量：107
2Monestam E, Wachtmeister L. Dissatisfaction with cataract surgery in relation to visual results in a population-based study in Sweden. J Cataract Refract Surg, 1999,25:1127-1134.
3Steinbery EP, Tielsch JM, Schein OD, et al. The VF-14: an index of functional impairment in patients with cataract. Arch Ophthalmol,1994,112:630-638.
4Mangione CM, Lee PP, Pitts J, et al. Psychometric properties of the national eye institute visual function questionnaire (NEI-VFQ). Arch Ophthalmol, 1998,116:1496-1504.
5Wolffsohn JS, Cochrane AL. Design of the low vision quality-of-life questionnaire (LVQOL) and measuring the outcome of low-vision rehabilitation. Am J Ophthalmol, 2000,130:793-802.
6Wolffsohn JS, Cochrane AL. Implementation methods for vision related quality of life questionnaires. Br J Ophthalmol, 2000,84:1035-1040.
7McDowell L, Newell C. Measuring health: a guide to rating scales and questionnaires. New York: Oxford University Press, 1987.330.
8Holladay JT, Prager TC. Mean visual acuity (letter). Am J Ophthalmol, 1991,111:372-374.
9Sommer A, Tielsch JM, Katz J, et al. Racial differences in the cause-specific prevalence of blindness in east Baltimore. N Engl J Med,1991,325:1412-1417.
10Klein R, Klein BE, Knudtson MD, et al. Prevalence of age- related macular degeneration in 4 racial/ethnic groups in the multi-ethnic study of atherosclerosis. Ophthalmology, 2006,113 : 373-380.